However, in low- and middle-income countries (LMIC) where molecular studies are yet not available, immunohistochemical stains (H3K27M, H3K27me3, H3G34R/V, IDH-1, R132H, ATRX, p53 olig-two and BRAF V600E) can be used in classifying high grade glioma according to the recent WHO classification for clinical management purpose. The gene discussed is TP53; the disease is glioma.